Yi Li Hua: Web3 is essentially the financial industry, benchmarking Web2 products as "misconceptions" on the development path
BlockBeats News, April 23rd, Liquid Capital (formerly LD Capital) founder Du Jun posted on social media:
"In the past wave of extinction of crypto VCs and projects, one core reason is that funding was basically spent on. Nurturing teams to develop useless Web3 products. The biggest misconception is benchmarking Web2 products. Essentially, Web3 is an industry, and there is no need to duplicate Web2 products. The most successful companies in the past crypto industry are all financial products, ranging from stablecoins, trading platforms to payment, and other successful companies are."
"Now with the arrival of the AI era, first, there is no need for large financing to recruit teams. Second, the new opportunity lies in AI + Finance. We believe that excellent founders with a few elites can build top-tier companies. This is currently the biggest opportunity for first-tier investment."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
BUZZ-3M India shares fall to 19-month low due to quarterly profit decline
Anthropic (ANT.US) to launch IPO roadshow next week, valuation may shrink from 1.5 trillion dollars to 1 trillion dollars! The AI capital feast faces a test.
After the AI sell-off, major investors are questioning whether Anthropic can go public at a $1.5 trillion valuation, or if it will be reduced to around $1 trillion. Fundraising may also decrease from $100 billion to $80 billion.
Crypto prices
More
